Individual ADCC capability predict treatment outcome under cetuximab-based therapy in head and neck cancer?

Authors:
  • LLL. Lattanzio
    L. Lattanzio
  • DVD. Vivenza
    D. Vivenza
  • FTF. Tonissi
    F. Tonissi
  • CVC. Varamo
    C. Varamo
  • MFM. Ferrero
    M. Ferrero
  • GSG. Strola
    G. Strola
  • GMG. Milano
    G. Milano
  • CNC. Lo Nigro
    C. Lo Nigro

Abstract
Introduction: Cetuximab is a IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) used for the treatment of local advanced-head and neck squamous cell carcinoma (LA-HNSCC). The working mechanism of cetuximab include the ability to develop antibody-dependent cell-mediated cytotoxicity (ADCC), triggered by the interaction of the Fc portion of the antibody with the Fc receptor on the immune cell, mainly on Natural Killer (NK) cells. Invariant NKT (iNKT) cells play an important role in the activation of immune cell subset, including NK cells, and their deficiency is related to poor clinical outcome in LA-HNSCC. The aim of this work was to investigate the predictive role of ADCC and iNKT in LA-HNSCC patients treated with cetuximab-based therapy.